News
Spexis AG appeals against trading suspension
Spexis AG, a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced that the company has lodged an appeal against the decision of SIX Exchange Regulation AG (SER) to suspend trading of its shares starting 3 June 2024
Type: industry
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
